Mahesh patel lipocine
http://www.drmaheshpatel.com/ WebDec 8, 2024 · The tentative approval is supported by a strong clinical and CMC data package. This is an important step towards getting our oral TRT no-titration option to patients. We are committed to working towards obtaining final approval of TLANDO," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine. Dr.
Mahesh patel lipocine
Did you know?
WebApr 3, 2024 · The study is expected to enroll a total of 12 participants and is being conducted at a single center in the US. Results are expected in the first half of 2024. "We are excited about our development progress for LPCN 1154," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. WebApr 3, 2024 · About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to …
WebDec 22, 2024 · SALT LAKE CITY, Dec. 22, 2024 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the... WebAssociate Vice President, Cardiovascular & Respiratory Therapeutic Area (TA) Merck. May 2024 - Present11 months. Section Head, Respiratory …
WebMar 1, 2024 · said Dr. Mahesh Patel, Chairman, President, and Chief Executive Officer of Lipocine. "We plan to submit an updated phase 3 protocol to the FDA for its review." …
WebMar 24, 2024 · Lipocine ( NASDAQ: LPCN) is owned by 11.87% institutional shareholders, 10.71% Lipocine insiders, and 77.42% retail investors. Israel Menahem Vizel is the largest individual Lipocine shareholder, owning 3.00M shares representing 3.39% of the company. Israel Menahem Vizel's Lipocine shares are currently valued at $984.00k.
WebMar 25, 2024 · Lipocine Inc. (NASDAQ:LPCN – Get Rating) CEO Mahesh V. Patel acquired 150,000 shares of Lipocine stock in a transaction on Friday, March 24th. The shares were bought at an average price of $0.32 per share, for a total transaction of $48,000.00. Following the purchase, the chief executive officer now owns 1,678,090 … recycling syringesWebNov 18, 2024 · Mahesh V. Patel has not been actively trading shares of Lipocine over the course of the past ninety days. Most recently, on Friday, March 24th, Mahesh V. Patel bought 150,000 shares of Lipocine stock. … klein\\u0027s pharmacy pelhamWebDec 19, 2024 · "We are excited to complete enrollment which leads to topline results mid-2024 for a serious end-stage condition with high unmet medical need," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. "Muscle disorder and hepatic encephalopathy (HE) are highly prevalent in cirrhotic patients, adversely impacting survival rates. klein\\u0027s kosher ice creamWebSep 15, 2024 · Sep 15, 2024, 08:00 ET. FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion … klein\\u0027s pharmacy cssWebLipocine’s CEO is Mahesh Patel, appointed in Jan 1997, they has a tenure of 26.3yrs. Their total yearly compensation is US$883.9k, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. They directly owns 1.9% of the company’s shares, worth US$537.0k. The average tenure of the management team and the board of ... klein\\u0027s shoprite pharmacyWebOct 18, 2024 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to … recycling tagung berlinWebSummary Presently, Mahesh V. Patel is President, Chief Executive & Financial Officer at Lipocine, Inc. He received an undergraduate degree from Karnataka University, a graduate degree from the University of Cincinnati (Ohio) and a doctorate from the University of Utah. Current positions of Mahesh V. Patel Holdings of Mahesh V. Patel recycling takeaway containers